Log in with your email address username.


[Articles] Eliglustat compared with imiglucerase in patients with Gaucher’s disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial

Oral eliglustat maintained haematological and organ volume stability in adults with Gaucher’s disease type 1 already controlled by intravenous ERT and could be a useful therapeutic option.